Pasar al contenido principal

ESTUDIO DE LA TRANSFORMACION LEUCEMICA DE LA DEFICIENCIA DE GATA2 MEDIANTE TECNICAS “OMICAS” EN MODELOS DE CELULAS MADRE HUMANAS

PID2020-115591RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency

  • Pera, Joan
  • García Hernández, Violeta
  • Berenguer Balaguer, Clara
  • Iglesias, Arnau
  • Spurk, Paulina
  • Pasquali, Lorenzo
  • Giorgetti, Alessandra
Patients with GATA2 deficiency are predisposed to developing myelodysplastic neoplasms (MDS), which can progress to acute myeloid leukemia. This progression is often associated with cytogenetic and somatic alterations. Mutations in SETBP1 and ASXL1 genes are recurrently observed in GATA2 patients, although their roles remain poorly understood. Here we develop a hiPSC-based system to investigate the impact of SETBP1 and ASXL1 mutations in GATA2 deficiency. Using precise genome editing, we recreate stepwise mutational trajectories observed in GATA2-related MDS. We demonstrate that GATA2 mutation has limited impact on hematopoietic progenitors, while the co-occurrence of SETBP1 or ASXL1 mutations impairs myeloid differentiation. The combination of all three mutations severely depletes myeloid progenitors, recapitulating GATA2-related MDS and highlighting their synergistic interplay. Notably, SETBP1 mutation plays a dominant role in establishing a stable chromatin accessibility landscape, even when co-occurring with ASXL1. Our study establishes an iPSC-based model of GATA2 deficiency, offering new insights into myeloid disease progression and a platform for testing future therapeutic strategies., We thank Dr. M.A. Mulaw - Ulm University and Dr. J. Pozniak - KU Leuven for their valuable advice and suggestions regarding the scATAC-seq analysis. This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Fondazione Pisana per la Scienza ONLUS (FPS-G01/2018), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00 / https://doi.org/10.13039/501100011033, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, by Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032, and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162). J.P. and M.D. were supported by Fundació La Marató TV3 228/C/2020. Z.Q. and Z.L. are supported by funding from the Shenzhen Bay Laboratory Startup Fund. D.R.M. was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. O.M.-B. was supported by 101029927-scGATA2track (H2020-MSCA-IF-2020) and he is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. P.S. received the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is LCF/BQ/DI22/11940009. M.M.M. was supported by the Government of Andorra with the predoctoral fellowship, ATC030-AND/2022. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". MCF received funding from "la Caixa" Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400014, PIXEL - TRANSCAN3-2021 (FAECC&ISCIII) and 2021 SGR 00888 - AGAUR 2022. The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927. We thank Dr. Pablo Menendez and Dr. Clara Bueno group for technical support and expertise during experimental procedures. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness

  • Romero-Moya, Damià
  • Torralba-Sales, Eric
  • Calvo, Cristina
  • Marin-Bejar, Oskar
  • Magallon-Mosella, Maria
  • Distefano, Maximiliano
  • Pera, Joan
  • Castaño, Julio
  • Giorgio, Francesca De
  • González, Jessica
  • Iglesias, Arnau
  • Berenguer Balaguer, Clara
  • Schilling, Marcel
  • Plass, Mireya
  • Pasquali, Lorenzo
  • Català, Albert
  • Molina, Oscar
  • Wlodarski, Marcin W.
  • Bigas Salvans, Anna
  • Giorgetti, Alessandra
GATA2 deficiency is a monogenic transcriptopathy disorder characterized by bone marrow failure (BMF), immunodeficiency, and a high risk of developing myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). Although informative mouse models have been developed, the mechanisms by which GATA2 haploinsufficiency drives disease initiation in humans remain incompletely understood. To address this, we developed a novel humanized model using CRISPR/Cas9 technology to knock-in GATA2-R398W variant in primary cord blood CD34+ cells. Additionally, we introduced specific mutations in SETBP1 and ASXL1 to model distinct premalignant stages of GATA2 deficiency. Through clonal competition and serial transplantation assays, we demonstrated that human CD34 cells harboring the GATA2 mutation exhibit significantly reduced fitness in vivo when competing with wild-type cells. Notably, this fitness disadvantage persists even when GATA2 mutations are combined with oncogenic SETBP1 and ASXL1 drivers, underscoring the dominant, deleterious effect of GATA2 deficiency on hematopoietic stem cell function. Functional in vitro analyses revealed that GATA2-R398W mutation impairs cell proliferation, disrupts cell cycle progression, and induces mitotic defects, which may contribute to hematopoietic stem/progenitor cell loss and impaired self-renewal. Transcriptomic profiles of GATA2-mutant cells revealed that these functional defects are associated with reduced HSC self-renewal capacity and upregulation of the pre-aging phenotype. Our work highlights the feasibility of generating a human GATA2 deficiency model suitable for studying the biological consequences of various GATA2 variants and the generation of a platform to test potential phenotype-rescuing therapeutics., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00/ https://doi.org/10.13039/501100011033, and PID2023-146290OB-I00, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032 and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162) and the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927 to OM-B. DR-M was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. JP and MD were supported by Fundació La Marató TV3 228/C/2020. MM-M was supported by the TC030-AND/2022 Predoctoral grant from the Government of Andorra. OM-B is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). The work of CC and OM was supported by the Spanish Ministry of Economy and Competitiveness/European Union NextGenerationEU (PID2022-142966OB-I00) and the Deutsche José Carreras Leukämie-Stiftung (DJCLS 15 R/2023) to OM. CC is supported by a predoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (PID2022-142966OB-I00). The work of MP was supported by a Ramón y Cajal contract of the Spanish Ministry of Science, Innovation and Universities (Grant: RYC2018-024564-I funded by MICIU/AEI/10.13039/501100011033 and by "El FSE invierte en tu futuro"). The work in the MP laboratory was supported by the project PID2022-139580OB-I00 funded by MICIU/AEI/10.13039/501100011033 and FEDER and by "ERDF A way of making Europe", by the European Union. MWW was supported by Evans MDS DRG grant and American Society of Hematology bridge award. Authors thank the members of the Advanced Optical Microscopy facility from UB (Scientific and Technological Centers, Universitat de Barcelona [CCiTUB]) for their technical support. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness

  • Romero-Moya, Damià
  • Torralba-Sales, Eric
  • Calvo, Cristina
  • Marin-Bejar, Oskar
  • Magallon-Mosella, Maria
  • Distefano, Maximiliano
  • Pera, Joan
  • Castaño, Julio
  • Giorgio, Francesca De
  • González, Jessica
  • Iglesias, Arnau
  • Berenguer Balaguer, Clara
  • Schilling, Marcel
  • Plass, Mireya
  • Pasquali, Lorenzo
  • Català, Albert
  • Molina, Oscar
  • Wlodarski, Marcin W.
  • Bigas Salvans, Anna
  • Giorgetti, Alessandra
GATA2 deficiency is a monogenic transcriptopathy disorder characterized by bone marrow failure (BMF), immunodeficiency, and a high risk of developing myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). Although informative mouse models have been developed, the mechanisms by which GATA2 haploinsufficiency drives disease initiation in humans remain incompletely understood. To address this, we developed a novel humanized model using CRISPR/Cas9 technology to knock-in GATA2-R398W variant in primary cord blood CD34+ cells. Additionally, we introduced specific mutations in SETBP1 and ASXL1 to model distinct premalignant stages of GATA2 deficiency. Through clonal competition and serial transplantation assays, we demonstrated that human CD34 cells harboring the GATA2 mutation exhibit significantly reduced fitness in vivo when competing with wild-type cells. Notably, this fitness disadvantage persists even when GATA2 mutations are combined with oncogenic SETBP1 and ASXL1 drivers, underscoring the dominant, deleterious effect of GATA2 deficiency on hematopoietic stem cell function. Functional in vitro analyses revealed that GATA2-R398W mutation impairs cell proliferation, disrupts cell cycle progression, and induces mitotic defects, which may contribute to hematopoietic stem/progenitor cell loss and impaired self-renewal. Transcriptomic profiles of GATA2-mutant cells revealed that these functional defects are associated with reduced HSC self-renewal capacity and upregulation of the pre-aging phenotype. Our work highlights the feasibility of generating a human GATA2 deficiency model suitable for studying the biological consequences of various GATA2 variants and the generation of a platform to test potential phenotype-rescuing therapeutics., This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00/ https://doi.org/10.13039/501100011033, and PID2023-146290OB-I00, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032 and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162) and the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927 to OM-B. DR-M was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. JP and MD were supported by Fundació La Marató TV3 228/C/2020. MM-M was supported by the TC030-AND/2022 Predoctoral grant from the Government of Andorra. OM-B is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). The work of CC and OM was supported by the Spanish Ministry of Economy and Competitiveness/European Union NextGenerationEU (PID2022-142966OB-I00) and the Deutsche José Carreras Leukämie-Stiftung (DJCLS 15 R/2023) to OM. CC is supported by a predoctoral fellowship from the Spanish Ministry of Economy and Competitiveness (PID2022-142966OB-I00). The work of MP was supported by a Ramón y Cajal contract of the Spanish Ministry of Science, Innovation and Universities (Grant: RYC2018-024564-I funded by MICIU/AEI/10.13039/501100011033 and by "El FSE invierte en tu futuro"). The work in the MP laboratory was supported by the project PID2022-139580OB-I00 funded by MICIU/AEI/10.13039/501100011033 and FEDER and by "ERDF A way of making Europe", by the European Union. MWW was supported by Evans MDS DRG grant and American Society of Hematology bridge award. Authors thank the members of the Advanced Optical Microscopy facility from UB (Scientific and Technological Centers, Universitat de Barcelona [CCiTUB]) for their technical support. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency

  • Pera, Joan
  • García Hernández, Violeta
  • Berenguer Balaguer, Clara
  • Iglesias, Arnau
  • Spurk, Paulina
  • Pasquali, Lorenzo
  • Giorgetti, Alessandra
Patients with GATA2 deficiency are predisposed to developing myelodysplastic neoplasms (MDS), which can progress to acute myeloid leukemia. This progression is often associated with cytogenetic and somatic alterations. Mutations in SETBP1 and ASXL1 genes are recurrently observed in GATA2 patients, although their roles remain poorly understood. Here we develop a hiPSC-based system to investigate the impact of SETBP1 and ASXL1 mutations in GATA2 deficiency. Using precise genome editing, we recreate stepwise mutational trajectories observed in GATA2-related MDS. We demonstrate that GATA2 mutation has limited impact on hematopoietic progenitors, while the co-occurrence of SETBP1 or ASXL1 mutations impairs myeloid differentiation. The combination of all three mutations severely depletes myeloid progenitors, recapitulating GATA2-related MDS and highlighting their synergistic interplay. Notably, SETBP1 mutation plays a dominant role in establishing a stable chromatin accessibility landscape, even when co-occurring with ASXL1. Our study establishes an iPSC-based model of GATA2 deficiency, offering new insights into myeloid disease progression and a platform for testing future therapeutic strategies., We thank Dr. M.A. Mulaw - Ulm University and Dr. J. Pozniak - KU Leuven for their valuable advice and suggestions regarding the scATAC-seq analysis. This work was supported by ERA PerMed GATA2-HuMo Funding Mechanism (Spain: Acció Instrumental de SLT011/18/00006 of the Department of Health of the Government of Catalonia), Fondazione Pisana per la Scienza ONLUS (FPS-G01/2018), Ministerio de Ciencia e Innovación, which is part of Agencia Estatal de Investigación (AEI), through the Retos Investigación grant, number PID2020-115591RB-I00 / https://doi.org/10.13039/501100011033, Fundació La Marató TV3 228/C/2020, Award no. AC23_2/00040 by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework, by Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovación", through the project number FORT23/00032, and Finançat per el Departament de Recerca i Universitats de la Generalitat de Catalunya i l'AGAUR (expedient 2021 SGR 00888) to AG. Funding for this project was provided in part by an EHA Research Grant award granted by the European Hematology Association (KOG-202109-01162). J.P. and M.D. were supported by Fundació La Marató TV3 228/C/2020. Z.Q. and Z.L. are supported by funding from the Shenzhen Bay Laboratory Startup Fund. D.R.M. was supported by Deutsche José Carreras Leukämie-Stiftung, DJCLS 13 R/2022. O.M.-B. was supported by 101029927-scGATA2track (H2020-MSCA-IF-2020) and he is currently supported by the Ramón y Cajal contract (RYC2021-032129-I) funded by AEI/European Social Fund UE. P.S. received the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is LCF/BQ/DI22/11940009. M.M.M. was supported by the Government of Andorra with the predoctoral fellowship, ATC030-AND/2022. The work in the LP laboratory was supported by "la Caixa" Foundation, LCF-PR-HR24-00150 and by PID2023-151556OB-I00 and CNS2024-154742 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by "ESF Investing in your future", by "ESF+" or by "European Union NextGenerationEU/PRTR". MCF received funding from "la Caixa" Foundation (ID 100010434), under the agreement LCF/PR/HR20/52400014, PIXEL - TRANSCAN3-2021 (FAECC&ISCIII) and 2021 SGR 00888 - AGAUR 2022. The work in AB laboratory was funded by ERA PerMed-Departament de Salut, Generalitat de Catalunya (SLT011/18/00007) and the EJP RD-Instituto de Salud Carlos III (AC23_2/00014). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 101029927. We thank Dr. Pablo Menendez and Dr. Clara Bueno group for technical support and expertise during experimental procedures. We thank the CERCA Programme/Generalitat de Catalunya for institutional support.